Renal cell cancer market to rapidly decline from 2019
The renal cell cancer market is expected to peak at a value of $2.7 billion in 2019, before significantly declining to $1.6 billion within three years, according to independent analysts Datamonitor Healthcare.
The decrease has been attributed to the patent expiry of key marketed brands including Novartis’ (NOVN: VX) Afinitor (everolimus), Roche’s (ROG: SIX) Avastin (bevacizumab), Pfizer’s (NYSE: PFE) Inlyta (axitinib), Sutent (sunitinib) and Torisel (temsirolimus), Bayer’s (BAYN: DE) Nexavar (sorafenib), and Votrient (pazopanib) from UK pharma major GlaxoSmithKline (LSE: GSK).
The sales of these are forecast to peak at $2.4 billion in 2018, before decreasing to $705 million in 2022 across the USA, Japan and five major EU markets of France, Germany, Italy, Spain and the UK. Sales of pipeline drugs will not be able to compensate for this loss in value over the forecast period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze